跳至主要内容
临床试验/NCT01539304
NCT01539304已完成3 期

Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of "CITUS Dry Syrup" in Children With Perennial Allergic Rhinitis: Double Blinded, Randomized, Placebo Controlled, Parallel Designed, Multi-centered, Phase III Study

SamA Pharmaceutical Co., Ltd1 个研究点 分布在 1 个国家目标入组 245 人开始时间: 2010年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
245
试验地点
1
主要终点
Mean change from baseline in NIS(Nasal Index Score) over the 4-week treatment period

研究概览

简要总结

Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of "CITUS Dry Syrup" in Children With Perennial Allergic Rhinitis: Double Blinded, Randomized, Placebo Controlled, Parallel Designed, Multi-centered, Phase III Study.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
24 Months 至 15 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Children aged over 24 months and under 15 years.
  • Patients who was diagnosed with perennial allergic rhinitis by ImmunoCAP test.
  • NIS mean total score of 1-week in baseline should be over 4.0.

排除标准

  • Patient who is accompanied by the seriously abnormal symptom in respiratory system, such as pneumonia, cystic fibrosis, viral influenza, tuberculosis, asthma(status praesens).
  • Patient who has cancer, diabetes mellitus, hypertension, CNS disease, and metabolic disease which need medication.
  • Patient who has rhinitis not caused by allergy.
  • Acute or chronic sinusitis.
  • Patient who has medical history of allergy in seasonal pollen during the trial.
  • Patient who has had eyes or nose surgery within 3 months prior to the trial.
  • Patient who has had eye or upper airway infection within 1 week prior to the treatment period.
  • Beginning immunotherapy or dose of change within 1 month prior to the trial.
  • Patient who has clinical history of sensitivity to allergic rhinitis medication.
  • Patient whose heart function is abnormal: including heart failure, abnormal ECG test value that is clinically significant.
  • Patient who has experience to have participated in other clinical trial within 2 months prior to the trial.
  • Patient who has taken contraindicated medications in this study within 1 week(baseline period) prior to the treatment period.
  • For girl who had her first period, result of pregnancy test was positive.

研究组 & 干预措施

CITUS Dry Syrup

Experimental

Pranlukast dry syrup 10%

干预措施: CITUS Dry Syrup (Drug)

Placebo

Placebo Comparator

Placebo

干预措施: Placebo (Drug)

结局指标

主要结局

Mean change from baseline in NIS(Nasal Index Score) over the 4-week treatment period

时间窗: 4 week treatment period (from baseline through the end of week 4)

Evaluation : from baseline(1-week prior to treatment)over the 4-week treatment(1-week prior to patients' last visit). NIS : Sum of 4 individual scores for Nasal congestion, Rhinorrhea, Sneezing, and Nasal itching, each rated by patients daily on a 4-point scale \[Score 0(best) to 3(worst)\].

次要结局

  • Use of rescue medication(from baseline through the end of week 4)
  • Assessing improvement of symptom by physician(from baseline through the end of week 4)
  • Assessing improvement of symptom by patient(from baseline through the end of week 4)
  • Mean change of Individual NIS(from baseline through the end of week 4)
  • Ratio distribution of NIS at end of week 4(from baseline through the end of week 4)
  • Cure rate(from baseline through the end of week 4)
  • Cure rate for each symptom(from baseline through the end of week 4)
  • Change of Instantaneous NIS(from baseline through the end of week 4)

研究者

发起方
SamA Pharmaceutical Co., Ltd
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Clinical Trial to Evaluate the Safety and Efficacy... | 临床试验